Literature DB >> 9792582

Hypertrophic cardiomyopathy in Greece: clinical course and outcome.

M Kyriakidis1, F Triposkiadis, A Anastasakis, A Theopistou, R Tocta, J Barbetseas, J Gialafos.   

Abstract

OBJECTIVE: Evaluation of clinical course and outcome of hypertrophic cardiomyopathy in a representative Greek population.
BACKGROUND: Hypertrophic cardiomyopathy is characterized by unexplained left ventricular hypertrophy and varied clinical expression. Recent studies suggest ethnic differences.
MATERIALS AND METHODS: One hundred seventy-four consecutive Greek patients (117 male, 57 female, age 47+/-16 years) from 143 different families were assessed at the Department of Cardiology of the University of Athens, Greece, and the State Cardiac Department, Hippokration Hospital, both located in Athens, Greece. To reduce selection bias, referral was based on disease diagnosis irrespective of clinical status or treatment needs. All patients were examined clinically, echocardiographically, and by ECG ambulatory monitoring at 6-month intervals for a period of 74+/-22 months (range, 8 to 108 months).
RESULTS: Most patients (n = 156, 89.7%) were in New York Heart Association (NYHA) functional class I or II. The disease was familial (at least one affected first-degree relative) in 81 of the 143 families (56.6%), and in 19 of these (13.3%) there was familial history of sudden cardiac death. At initial examination, intraventricular septal thickness was 17.3+/-4.1 mm and posterior wall thickness was 13.7+/-3.8 mm and a left ventricular outflow gradient >30 mm Hg was present in 58 patients (33.3%). Similar were the findings during the last examination (17.5+/-4.3 mm, 13.5+/-4.4 mm, and 56 (32.2%, respectively, p = not significant). Episodes of nonsustained ventricular tachycardia were noted in 15 patients (8.6%). There were eight deaths during follow-up: four sudden deaths and four from intractable heart failure. Syncope was reported by all patients who died. The annual mortality in this study was 1%. Syncope and NYHA class were the only predictors of outcome.
CONCLUSIONS: In this representative Greek patient cohort with hypertrophic cardiomyopathy, the arrhythmogenic substrate was modest and the clinical course benign. Sudden cardiac death was infrequent and syncope, functional class, and ventricular arrhythmias were the only predictors of a poor outcome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9792582     DOI: 10.1378/chest.114.4.1091

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  4 in total

1.  Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands.

Authors:  I Christiaans; E A Nannenberg; D Dooijes; R J E Jongbloed; M Michels; P G Postema; D Majoor-Krakauer; A van den Wijngaard; M M A M Mannens; J P van Tintelen; I M van Langen; A A M Wilde
Journal:  Neth Heart J       Date:  2010-05       Impact factor: 2.380

2.  Low prevalence of cardiac troponin T mutations in a Greek hypertrophic cardiomyopathy cohort.

Authors:  A Miliou; A Anastasakis; L G D'Cruz; A Theopistou; A Rigopoulos; I Rizos; S Stamatelopoulos; P Toutouzas; C Stefanadis
Journal:  Heart       Date:  2005-07       Impact factor: 5.994

3.  The prognostic value of standardized reference values for speckle-tracking global longitudinal strain in hypertrophic cardiomyopathy.

Authors:  Gregory R Hartlage; Jonathan H Kim; Patrick T Strickland; Alan C Cheng; Nima Ghasemzadeh; Maria A Pernetz; Stephen D Clements; B Robinson Williams
Journal:  Int J Cardiovasc Imaging       Date:  2015-01-14       Impact factor: 2.357

4.  Modes of death and clinical outcomes in adult patients with hypertrophic cardiomyopathy in Thailand.

Authors:  Nattakorn Songsirisuk; Veraprapas Kittipibul; Nilubon Methachittiphan; Vorawan Charoenattasil; Nath Zungsontiporn; Ittikorn Spanuchart; Saranya Buppajarntham; Charoen Mankongpaisarnrung; Sudarat Satitthummanid; Suphot Srimahachota; Pairoj Chattranukulchai; Smonporn Boonyaratavej Songmuang; Sarinya Puwanant
Journal:  BMC Cardiovasc Disord       Date:  2019-01-03       Impact factor: 2.298

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.